Neogen vs Intellia Therapeutics: revenue, profit, margins and growth compared
Neogen brought in $870.4M of revenue in fiscal 2026, Intellia Therapeutics $67.7M in fiscal 2025. Revenue changed by -2.7% at Neogen and +16.9% at Intellia Therapeutics on the year before, so Intellia Therapeutics grew faster. Neogen kept -0.9% of its revenue as net profit, Intellia Therapeutics -609.9%. Free cash flow was $31.9M at Neogen and -$395.9M at Intellia Therapeutics.
Fiscal years as each company reports them; the two may end in different months.
Questions about Neogen and Intellia Therapeutics
Which is bigger by revenue, Neogen or Intellia Therapeutics?
Neogen is bigger by revenue: $870.4M in fiscal 2026, against $67.7M for Intellia Therapeutics in fiscal 2025.
Which keeps more of its revenue as profit, Neogen or Intellia Therapeutics?
Neogen had a net margin of -0.9% in fiscal 2026; Intellia Therapeutics had -609.9% in fiscal 2025.
Which grew revenue faster, Neogen or Intellia Therapeutics?
In their latest fiscal years revenue changed by -2.7% at Neogen and +16.9% at Intellia Therapeutics.
Where do these numbers come from?
From the annual reports each company files with the SEC (10-K, or 20-F and 40-F for foreign companies), read from their XBRL data. Margins and growth are simple arithmetic on those figures. Nothing here is a recommendation.